Dose-escalation Study of Lupartumab Amadotin (BAY1129980)

The relatively restricted C4.4a expression pattern provides a target for the selective
delivery of a cytotoxic drug to C4.4.a-expressing tumor cells by means of a suitable
antibody-drug conjugate. The subject population eligible for the current study will be those
subjects with advanced malignancies known to express C4.4a, which are refractory to standard
therapy or those without standard therapy or actively refusing any treatment, which would be
regarded as standard and in whom, in the opinion of the investigator, experimental therapy
with BAY1129980 may be beneficial.Depending on the number of dose-escalating steps and the
occurrence of DLTs, the planned numbers of subjects could vary.It is expected that up to 90
subjects may participate in the dose-expansion phase of the study and up to 6-9 subjects may
particpate in the dose re-esclation phase.The study assessments in the expansion phase of the
study are identical to those in the dose-escalation phase.

Amendment # 3 includes changes to DLT criteria (hematological and non-hematological) and
allows for frequent follow-up for subjects experiencing drug-related liver toxicity that
warrants dose reduction or dose interruptions.

Inclusion Criteria:

- All subjects must be ≥ 18 years at the first screening examination / visit

- All subjects must provide a tumor tissue sample from [Formalin Fixed Paraffin Embedded
(FFPE) slides] archival tissue or fresh biopsy collected before Cycle 1, Day 1

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1

- Life expectancy of at least 12 weeks

- Radiographically or clinically evaluable tumor. In the expansion phase, disease must
be measurable according to RECIST 1.1.

- Adequate bone marrow, liver, and renal function

- Histologically or cytologically confirmed solid tumors known to express C4.4a (eg,
carcinomas of the lung, head & neck SCC, esophagus SCC (squamous cell
carcinoma),colon, ovary, prostate, and breast) that are refractory to any standard
therapy, or have no standard therapy available, or for which subjects actively refuse
any treatment that would be regarded as standard and in whom, in the opinion of the
investigator, experimental therapy with BAY1129980 may be beneficial.

- A signed informed consent must be obtained prior to any study-specific procedures.

- Measurable disease with at least one lesion that can be accurately measured in at
least one dimension according to RECIST 1.1

Exclusion Criteria:

- Anticancer chemotherapy, experimental cancer therapy, or cancer immunotherapy within 4
weeks prior to first dose study drug. Anticancer therapy is defined as any agent or
combination of agents with clinically proven anti tumor activity administered by any
route with the purpose of affecting the malignancy, either directly or indirectly,
including palliative and therapeutic endpoints.

- Skin toxicity including but not limited to erythema, rash, ulceration, and open wound
that is still clinically present and considered as acute or chronic.

- Subjects with psoriasis or other severe skin disease (eg, autoimmune skin disease,
active erythematous skin lesions, etc.)

- Serious, non-healing wound, skin ulcer (of any grade), or bone fracture.

- Prior local radiotherapy is allowed if it is completed at least 4 weeks prior to the
first dose of study drug and the subject has evaluable lesions not previously
irradiated

- Significant liver dysfunction determined as Child-Pugh score B or C

- History of symptomatic metastatic brain or meningeal tumors unless the subject is >3
months from the end of definitive therapy before the first dose of study drug and has
clinically or radiologically no evidence of tumor growth.

- History of clinically significant cardiac disease.

- Anti-platelet drugs within 4 weeks prior to the first dose of study drug.
Anti-platelet drugs are defined as any agent or combination of agents with clinically
proven anti-thrombotic activity administered by any route with the purpose of
affecting blood clotting ability of the subject.

- Participation in another clinical trial in which they received active therapy within 4
weeks prior to the first dose of study drug.

- Subjects with CNS symptoms should undergo a CT scan or MRI of the brain to exclude new
or progressive brain metastases. Spinal cord metastasis is acceptable. However,
subjects with spinal cord compression should be excluded.

- Subjects with severe renal impairment (GFR <50 mL/min/1.73 m²) or on dialysis.

- History of organ allograft (except for corneal transplant) or autologous or allogeneic
bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of
study drug.

- Current evidence or previous medical history of (ie, any absolute risk of latent
infection) hepatitis B or C, any active hepatitis, or human immunodeficiency virus
(HIV) infection. Active clinically serious infections > CTCAE Grade 2.

- Major surgery or significant trauma within 2 weeks prior to the first dose of study
drug.

- Substance abuse, medical, psychological or social conditions that may interfere with
the subject's participation in the study or evaluation of the study result.

- Subjects who are pregnant or are breast-feeding.

- Any condition that is unstable or could jeopardize the safety of the subject and his /
her compliance to the study.